Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Epidermal growth factor receptor（EGFR） is a potential target for new anticancer therapy in
head and neck squamous cell carcinoma, because blocking the EGFR by a monoclonal antibody
results in inhibition of the stimulation of the receptor, therefore, in inhibition of cell
proliferation, enhanced apoptosis, and reduced angiogenesis, invasiveness and metastases. The
study hypothesis is that neo-adjuvant Erbitux-based chemotherapy followed by surgery and
radiotherapy for locally advanced oral/oropharyngeal cancer could benefit the patients on
prognosis. The endpoints of this study are the pathological complete response after
neo-adjuvant Erbitux-based chemotherapy followed by surgery and radiotherapy, the survival
rate, and the safety.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborators:
Fudan University Second Military Medical University Tongji University